Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV001508785 | SCV001715155 | uncertain significance | not provided | 2020-10-13 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001508785 | SCV002585590 | likely benign | not provided | 2022-09-01 | criteria provided, single submitter | clinical testing | PLCG2: BP4 |
Fulgent Genetics, |
RCV002506590 | SCV002817078 | uncertain significance | Familial cold autoinflammatory syndrome 3; Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation | 2021-10-29 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002567997 | SCV003467222 | uncertain significance | Familial cold autoinflammatory syndrome 3 | 2024-11-11 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 1165 of the PLCG2 protein (p.Val1165Ile). This variant is present in population databases (rs372557475, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with PLCG2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1163585). An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Benign". The isoleucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |